TipRanks
Go Ultimate55% OFF

Clover Health Investments (7QD) AI Stock Analysis

0 Followers
DE:7QD

Clover Health Investments

(Frankfurt:7QD)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Membership and earnings growthRapid membership expansion alongside strong revenue growth indicates increasing scale and market adoption. If Clover can retain members and manage care costs effectively, the larger platform should support greater operating leverage and a more durable earnings base over the next several quarters.
Negative Factors
Very thin profitabilityAlthough Clover has reached positive TTM earnings, sub-1% net margins leave little protection against medical-cost increases or operating-expense volatility. Durable profitability therefore remains unproven, and relatively modest adverse claims or spending changes could materially reduce earnings.

Clover Health Investments (7QD) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%125%DE:7QD+72.83%EWG+3.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 2.38B
Dividend Yield
―
Average Volume (3M)
344
Price to Earnings (P/E)
263.5
Beta (1Y)
0.48
Revenue Growth
46.70%
EPS Growth
―
Country
Germany
Employees
724
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

Clover Health Investments Business Overview & Revenue Model

Company Description

Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Mainte...

Clover Health Investments Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentPositive

The call was strongly positive, with substantial membership, revenue, gross profit, EBITDA and net income growth; improved full-year guidance; expected first full-year GAAP profitability; leading Star Ratings and HEDIS performance; favorable cohort economics; and encouraging early 2027 enrollment results. The company also identified meaningful earnings expansion opportunities from cohort maturation and operating leverage. Offsetting issues included elevated outpatient utilization, a planned seasonal fourth-quarter EBITDA loss, a near-term earnings drag from new members, a pending government appeal and management's criticism of the current Stars measurement framework.

Positive Updates

Expected First Full Year of GAAP Profitability
Clover expects to deliver its first full year of GAAP net income profitability in 2026. Through the first nine months, GAAP net income improved by nearly $100 million, and year-to-date GAAP net income increased by $98 million to $62 million.

Negative Updates

Elevated Outpatient Utilization
Although inpatient utilization trends were favorable, outpatient utilization remained elevated year-over-year. Management said the increase was in line with its initial outlook.

Company Guidance

For full year 2026, Clover expects average Medicare Advantage membership of 157,000 to 158,000 members, total revenue of $2.97 billion to $3 billion, consolidated gross profit of $540 million to $555 million, adjusted EBITDA of $75 million to $85 million and GAAP net income of $25 million to $35 million; for the full year, it expects adjusted SG&A ratio improvement at or above its original target of 100 basis points to 150 basis points, while the fourth quarter is expected to include lower consolidated gross profit from normal medical cost seasonality, higher SG&A as planned AEP investments increase and the seasonal adjusted EBITDA loss already contemplated in guidance. Clover is not providing formal guidance for 2027 or 2028, but expects another strong year of membership growth, meaningful earnings expansion in 2027 and momentum into 2028, with insurance gross profit per member per month approximately $70 higher in year 2 than in year 1 and approximately $85 higher in year 3 than in year 2; approximately half of current membership comprises the 2025 and 2026 cohorts, with 21% of members in their second year this year and 28% in year 1.

Clover Health Investments Risk Analysis

Clover Health Investments disclosed 67 risk factors in its most recent earnings report. Clover Health Investments reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Our failure to protect our sites, networks, and systems against security breaches, or otherwise to protect our confidential or health information or the confidential or health information of our members, providers, or other third parties, could damage our reputation and brands, and substantially harm our business and results of operations.Q2, 2026

Clover Health Investments Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:7QD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ELVELV69Neutral$93.81B18.4011.59%1.59%3.60%-4.06%
CNCCNC66Neutral$37.63B25.066.78%―9.71%―
UNHUNH62Neutral$366.81B22.5916.35%2.29%3.33%-8.75%
ALHCALHC60Neutral$1.70B53.6912.46%―35.87%―
HUMHUM58Neutral$50.12B38.646.91%0.86%18.33%-18.53%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:7QDCNCHUMUNHELVALHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:7QD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:7QDClover Health Investments Corp3.831.5467.18%
CNCCentene69.7435.49103.62%
HUMHumana433.74198.3984.30%
UNHUnitedhealth Group Inc.394.1580.9125.83%
ELVElevance Health, Inc.425.62127.7642.89%
ALHCAlignment Healthcare, Inc.7.56-8.82-53.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.